From December 16th to December18th 2016, P4 China-International Precision Medicine Convention was held in Beijing successfully. There were 60 regulators, leading experts and well-known enterprise executives from home and abroad attended the convention. Dr. Wei, the CSO of EdiGene, was invited to attend the convention and made a speech.
Antibodies are essential tools for both basic and clinical research. However, there has been growing distrust of commercially available antibodies with regard to specificity and performance variability. As a result, the research community and funding agencies have demanded that antibody suppliers increase their efforts to more thoroughly validate these reagents. One approach to address this is through knockout of the target protein by CRISPR technologies.
BEIJING, June 28, 2017. EdiGene Inc. announced today that BioLegend, a world renowned manufacturer of biomedical research reagents, is teaming up with EdiGene, a genome editing company, to validate its Cell Biology portfolio antibodies using EdiGene’s extensive repository of 100% knockout (KO) cell lines. BioLegend takes antibody validation very seriously and guarantees antibody specificity of over 15,000+ antibody products.